InsuletKPI data tables
Insulet operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Cash |
|---|---|
| Q2 2026 | 534.9 |
| Q1 2026 | 480 |
| Q4 2025 | 716.1 |
| Q3 2025 | 757.4 |
| Q2 2025 | 1,121.6 |
| Q1 2025 | 1,283.1 |
| Q4 2024 | 953.4 |
| Q3 2024 | 902.6 |
| Q2 2024 | 821 |
| Q1 2024 | 751.2 |
| Q4 2023 | 704.2 |
| Q3 2023 | 685.4 |
| Q2 2023 | 660.1 |
| Q1 2023 | 620.7 |
| Q4 2022 | 674.8 |
| Q3 2022 | 722 |
| Q2 2022 | 708.6 |
| Q1 2022 | 709.6 |
| Q4 2021 | 791.6 |
| Q3 2021 | 856.6 |
Source: Insulet Form 10-Q / Form 10-K condensed consolidated balance sheet, period-end cash and cash equivalents (SEC XBRL https://data.sec.gov/api/xbrl/companyfacts/CIK0001145197.json). Instant 10-Q/10-K facts only; later filing wins. us-gaap:CashAndCashEquivalentsAtCarryingValue through Q3 2021; afterward the printed cash line equals us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents minus us-gaap:RestrictedCashNoncurrent (compensating balance in other assets; 0 when untagged). Not FCF. The $500 million undrawn revolver is not plotted. Unit usd_millions. Window Q3 2021–Q2 2026. Q3 2021 $856.6 million: 10-Q ended 2021-09-30 https://www.sec.gov/Archives/edgar/data/1145197/000114519721000041/0001145197-21-000041-index.htm. Latest XBRL Q2 2026 $534.9 million: 10-Q ended 2026-06-30 https://www.sec.gov/Archives/edgar/data/1145197/000114519726000169/0001145197-26-000169-index.htm. Existing earnings-call rounded million kept on overlap (same package, not restated): Q1 2026 $480 (XBRL 480.4).
| Period | Omnipod, United States | Omnipod, International | Drug Delivery |
|---|---|---|---|
| Q2 2026 | 544.1 | 251.8 | 5.8 |
| Q1 2026 | 515.6 | 242.9 | 3.3 |
| Q4 2025 | 567.8 | 214 | 2 |
| Q3 2025 | 497.1 | 202.1 | 7.1 |
| Q2 2025 | 453.2 | 185.8 | 10.2 |
| Q1 2025 | 401.7 | 152.3 | 14.9 |
Source: Insulet Form 8-K Exhibit 99.1 earnings releases, revenue by geography (U.S. and International Omnipod, and Drug Delivery), three months ended. Q1 2025 is the comparative in the Q1 2026 release, which restated international from $152.4 million to $152.3 million. Q2 2025: https://www.sec.gov/Archives/edgar/data/1145197/000114519725000037/podd2025-06x30ex991.htm. Q3 2025: https://www.sec.gov/Archives/edgar/data/1145197/000114519725000067/podd2025-09x30ex991.htm. Q4 2025: https://www.sec.gov/Archives/edgar/data/1145197/000114519726000026/podd202512-31ex991.htm. Q1 2026: https://www.sec.gov/Archives/edgar/data/1145197/000114519726000100/podd2026-03x31ex991.htm. Q2 2026: https://www.sec.gov/Archives/edgar/data/1145197/000114519726000167/podd2026-06x30ex991.htm.